Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract

Gennaro A. Carpinito, Walter M. Stadler, Joseph V. Briggman, Gerald W. Chodak, Paul A. Church, Donald L. Lamm, Paul H. Lange, Edward M. Messing, Robert M. Pasciak, George B. Reservitz, Robert N. Ross, Daniel B. Rukstalis, Michael F. Sarosdy, Mark S. Soloway, Robert P. Thiel, Nicholas Vogelzang, Cheryl L. Hayden

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Purpose: The purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22,* as an indicator for transitional cell carcinoma of the urinary tract. Materials and Methods: Three groups of subjects participated in this trial of NMP22:1-175 with transitional cell carcinoma, 2-117 with benign urinary tract conditions and 3-375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22. Results: In normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels. Conclusions: NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer.

Original languageEnglish
Pages (from-to)1280-1285
Number of pages6
JournalJournal of Urology
Volume156
Issue number4
StatePublished - Oct 1 1996

Fingerprint

Nuclear Matrix-Associated Proteins
Transitional Cell Carcinoma
Urinary Tract
Healthy Volunteers
Tumor Biomarkers
Time and Motion Studies
nuclear matrix protein 22
Nonparametric Statistics
Immunoassay
Neoplasms
Urine

Keywords

  • bladder
  • bladder neoplasms
  • carcinoma
  • nuclear matrix
  • nuclear proteins
  • transitional cell

ASJC Scopus subject areas

  • Urology

Cite this

Carpinito, G. A., Stadler, W. M., Briggman, J. V., Chodak, G. W., Church, P. A., Lamm, D. L., ... Hayden, C. L. (1996). Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. Journal of Urology, 156(4), 1280-1285.

Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. / Carpinito, Gennaro A.; Stadler, Walter M.; Briggman, Joseph V.; Chodak, Gerald W.; Church, Paul A.; Lamm, Donald L.; Lange, Paul H.; Messing, Edward M.; Pasciak, Robert M.; Reservitz, George B.; Ross, Robert N.; Rukstalis, Daniel B.; Sarosdy, Michael F.; Soloway, Mark S.; Thiel, Robert P.; Vogelzang, Nicholas; Hayden, Cheryl L.

In: Journal of Urology, Vol. 156, No. 4, 01.10.1996, p. 1280-1285.

Research output: Contribution to journalArticle

Carpinito, GA, Stadler, WM, Briggman, JV, Chodak, GW, Church, PA, Lamm, DL, Lange, PH, Messing, EM, Pasciak, RM, Reservitz, GB, Ross, RN, Rukstalis, DB, Sarosdy, MF, Soloway, MS, Thiel, RP, Vogelzang, N & Hayden, CL 1996, 'Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract', Journal of Urology, vol. 156, no. 4, pp. 1280-1285.
Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. Journal of Urology. 1996 Oct 1;156(4):1280-1285.
Carpinito, Gennaro A. ; Stadler, Walter M. ; Briggman, Joseph V. ; Chodak, Gerald W. ; Church, Paul A. ; Lamm, Donald L. ; Lange, Paul H. ; Messing, Edward M. ; Pasciak, Robert M. ; Reservitz, George B. ; Ross, Robert N. ; Rukstalis, Daniel B. ; Sarosdy, Michael F. ; Soloway, Mark S. ; Thiel, Robert P. ; Vogelzang, Nicholas ; Hayden, Cheryl L. / Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. In: Journal of Urology. 1996 ; Vol. 156, No. 4. pp. 1280-1285.
@article{fb5b7200879b4af28985468dcdeedbeb,
title = "Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract",
abstract = "Purpose: The purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22,* as an indicator for transitional cell carcinoma of the urinary tract. Materials and Methods: Three groups of subjects participated in this trial of NMP22:1-175 with transitional cell carcinoma, 2-117 with benign urinary tract conditions and 3-375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22. Results: In normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels. Conclusions: NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer.",
keywords = "bladder, bladder neoplasms, carcinoma, nuclear matrix, nuclear proteins, transitional cell",
author = "Carpinito, {Gennaro A.} and Stadler, {Walter M.} and Briggman, {Joseph V.} and Chodak, {Gerald W.} and Church, {Paul A.} and Lamm, {Donald L.} and Lange, {Paul H.} and Messing, {Edward M.} and Pasciak, {Robert M.} and Reservitz, {George B.} and Ross, {Robert N.} and Rukstalis, {Daniel B.} and Sarosdy, {Michael F.} and Soloway, {Mark S.} and Thiel, {Robert P.} and Nicholas Vogelzang and Hayden, {Cheryl L.}",
year = "1996",
month = "10",
day = "1",
language = "English",
volume = "156",
pages = "1280--1285",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract

AU - Carpinito, Gennaro A.

AU - Stadler, Walter M.

AU - Briggman, Joseph V.

AU - Chodak, Gerald W.

AU - Church, Paul A.

AU - Lamm, Donald L.

AU - Lange, Paul H.

AU - Messing, Edward M.

AU - Pasciak, Robert M.

AU - Reservitz, George B.

AU - Ross, Robert N.

AU - Rukstalis, Daniel B.

AU - Sarosdy, Michael F.

AU - Soloway, Mark S.

AU - Thiel, Robert P.

AU - Vogelzang, Nicholas

AU - Hayden, Cheryl L.

PY - 1996/10/1

Y1 - 1996/10/1

N2 - Purpose: The purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22,* as an indicator for transitional cell carcinoma of the urinary tract. Materials and Methods: Three groups of subjects participated in this trial of NMP22:1-175 with transitional cell carcinoma, 2-117 with benign urinary tract conditions and 3-375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22. Results: In normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels. Conclusions: NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer.

AB - Purpose: The purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22,* as an indicator for transitional cell carcinoma of the urinary tract. Materials and Methods: Three groups of subjects participated in this trial of NMP22:1-175 with transitional cell carcinoma, 2-117 with benign urinary tract conditions and 3-375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22. Results: In normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels. Conclusions: NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer.

KW - bladder

KW - bladder neoplasms

KW - carcinoma

KW - nuclear matrix

KW - nuclear proteins

KW - transitional cell

UR - http://www.scopus.com/inward/record.url?scp=9544247720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544247720&partnerID=8YFLogxK

M3 - Article

C2 - 8808854

AN - SCOPUS:9544247720

VL - 156

SP - 1280

EP - 1285

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -